Case study — A stable triple-API topical, from development to a successful First-in-Human study
How Zelmic and CTC took a US biotech’s complex topical candidate from formulation all the way to a completed Phase I trial — within one integrated pathway. The challenge A US-based biotech approached the CTR Group with an ambitious topical candidate: a single formulation combining three active pharmaceutical ingredients (APIs). Combining three actives in one…
Continue Reading
